,3,4 With anti-TNFα therapy rapidly becoming the standard first-line treatment, particularly in severe Crohn’s disease (CD), developing reliable biomarkers of treatment response would augment personalized clinical decision-making by allowing for the early prediction of patient response to anti-TNFα therapy.5 This evidence concerns the gene TNF and Crohn disease.